Results 41 to 50 of about 552 (131)

Risk of secondary bacterial infections during treatment with anti-inflammatory genetically engineered biological drugs in COVID-19 patients

Фармация и фармакология (Пятигорск)
The aim of the work was to identify the presence and strength of association between the use of anti-inflammatory genetically engineered biological drugs and the development of secondary bacterial infections in COVID-19 patients.Materials and methods. We
V. I. Petrov, A. Yu. Ryazanova, N. S. Tokareva   +2 more
doaj   +1 more source

IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab [PDF]

Annals of the Rheumatic Diseases, 2014
The combination of synthetic disease-modifying anti-rheumatic drugs (sDMARDs) such as methotrexate (MTX) and biologic DMARDs (bDMARDs) targeting inflammatory cytokines such as tumour necrosis factor (TNF) has enabled markedly efficient control of disease activity in patients with rheumatoid arthritis (RA) with inadequate response to MTX (MTX-IR).1–7 ...
Yoshiya, Tanaka, Emilio, Martin Mola
openaire   +2 more sources

Effect of interleukin 6 blockers on body composition, adipocytokines and insulin-like growth factor 1 in patients with rheumatoid arthritis

Научно-практическая ревматология
The aim – to study the effect of interleukin (IL) 6 blockers on body composition, as well as leptin, adiponectin, and insulin-like growth factor (IGF) 1 levels in patients with rheumatoid arthritis (RA) during a prospective follow-up of 6 months.Material
L. V. Kondratyeva, Yu. N. Gorbunova, T. V. Popkova, A. A. Abramkin, T. A. Lisitsyna, N. V. Demin, M. E. Diatroptov, A. S. Avdeeva   +7 more
doaj   +1 more source

Analysis of Management of Patients with COVID-19 in a Temporary Infectious Diseases Hospital Deployed on the Facilities of Republican TB Dispensary, the Republic of Tatarstan

Туберкулез и болезни лёгких, 2022
COVID-19 is a viral infection and its prevalence requires investigation of different co-morbid conditions including tuberculosis, as well as operation of temporary infectious diseases hospitals (TIDH) for the treatment of COVID-19 deployed on the ...
A. A. Vizel, S. A. Shayakhmetova, A. P. Alekseev, I. Yu. Vizel, A. V. Nikitin, A. A. Galimov   +5 more
doaj   +1 more source

Switching from interleukin-6 receptor inhibitors to the direct interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis: efficacy and safety during one year of therapy

Современная ревматология
Objective: to investigate the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) over a 12-month period after switching from interleukin (IL)-6 receptor inhibitors (iIL6R) for non-medical reasons.Material and methods.
P. A. Shesternya, A. A. Baranov, I. B. Vinogradova, O. N. Anoshenkova, O. V. Antipova, E. A. Bogdanova, Yu. Yu. Grabovetskaya, E. P. Ilivanova, A. N. Kalyagin, A. A. Blinova, N. A. Lapkina, M. V. Mokrousova, O. B. Nesmeyanova, N. M. Nikitina, N. V. Yudina, E. N. Alekseev, E. L. Nasonov, A. M. Lila   +17 more
doaj   +1 more source

Olokizumab therapy and cardiovascular complications in rheumatoid arthritis

Rheumatology Science and Practice
The development of cardiovascular disorders associated with atherosclerotic vascular lesions is a common complication of autoimmune rheumatic diseases (AIRDs), leading to a life expectancy decrease. Rheumatoid arthritis (RA) has a special place among the AIRDs, and the incidence of atherosclerotic vascular disease is 1.5-fold higher than in the general
E. V. Zonova, A. A. Baranov, A. N. Egorova, M. S. Lemak, S. M. Kuzkina, E. L. Nasonov   +5 more
openaire   +1 more source

Immunomodulatory drug therapy for the disease caused by SARS-CoV-2 infection (COVID-19)

Alʹmanah Kliničeskoj Mediciny, 2020
This systematic review focuses on the state-of-the-art pharmacotherapy of immune disorders in the novel coronavirus infection (COVID-19), leading to a cytokine storm and uncontrolled inflammatory response that causes severe tissue damage and multiple ...
D. E. Karateev, E. L. Luchikhina
doaj   +1 more source

The Effect of Potentially Hepatotoxic Medicinal Products on Alanine Transaminase Levels in COVID-19 Patients: A Case–Control Study

Безопасность и риск фармакотерапии
INTRODUCTION. Elevated liver enzyme levels are common in patients with COVID-19. Personalised prescribing to reduce the risk of hepatotoxicity requires studying the role of pharmacotherapy in the development of liver dysfunction in COVID-19 patients.AIM.
V. I. Petrov, A. Yu. Ryazanova, N. S. Tokareva   +2 more
doaj   +1 more source

Assessment of Clinical Efficacy of Dexamethasone in Patients with Moderate COVID-19

Общая реаниматология, 2022
The host immune response, primarily manifested by hypercytokinemia, obviously plays a key role in the development of severe novel coronavirus disease, COVID-19.
M. V. Tolochko, I. N. Leyderman, O. A. Khokhunov, V. A. Mazurok, R. E. Rzheutskya   +4 more
doaj   +1 more source

Efficacy and safety of olokizumab, interleukin-6 inhibitor, in hospitalized patients with COVID-19

Clinical pharmacology and therapy, 2022
Olokizumab is a new humanised monoclonal antibody targeting interleukin 6 ligand. Olokizumab was developed for treatment of rheumatoid arthritis. In Russia, it was also approved for treatment of COVID-19-associated hyperinflammatory syndrome. This article presents two case reports of COVID-19 patients and reviews the indications for olokizumab ...
S. Moiseev, P. Potapov, V. Nadtocheeva, L. Akulkina, M. Brovko, P. Novikov   +5 more
openaire   +1 more source